Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects

NCT01619345 · Completed

Last updated 2026-05-28

This study tested how a tablet dissolves in the stomach or small intestine of healthy men to understand where it breaks down completely.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 27 people

Who can join Ages 18–64 · male only Healthy volunteers accepted.

Timeline Started 2012-06 · est. completion 2012-08

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT01619345 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to investigate whether the volume of water administered with NN9924 affects the anatomical location (stomach or proximal small bowel) of tablet erosion.

Treatments tested

semaglutide also known as NN9924 Drug

Subjects will be treated with two single doses of 10 mg semaglutide in a tablet. Dosing will be done on 2 dosing visits separated by 4 to 6 weeks.

Main thing measured	Anatomical location (stomach or proximal small bowel) of tablet at complete tablet erosion (CTE)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Healthy
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01619345 ↗